PEX1 Gene Peroxisome Biogenesis Disorder Type 1B Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

This DHA-licensed genetic test delivers 99.9% diagnostic sensitivity via next‑generation sequencing (NGS), with ISO‑certified premium home collection and post‑test clinical genetic counselling. The analysis adheres to the highest data privacy standards under UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.

✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
✓ Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation by a qualified genetic counsellor.
✓ Insurance Support: Direct Billing Verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The PEX1 Genetic Test screens for pathogenic variants in the PEX1 gene causing peroxisome biogenesis disorder type 1B, a severe neurological and multisystem condition inherited in an autosomal recessive manner. This NGS‑based assay provides comprehensive coverage of the entire coding region and splice sites.

Feature	Our NGS PEX1 Test	Closest Alternative
Diagnostic Precision	Comprehensive gene‑wide analysis; >99.9% analytical sensitivity/specificity for SNVs and small indels	Biochemical VLCFA panel or limited Sanger sequencing (only known hotspots)
Methodology	Next‑Generation Sequencing (NGS) with bioinformatic validation	Capillary sequencing of selected exons / plasma very‑long‑chain fatty acid assay
Turnaround Time	3 to 4 Weeks	4 to 6 Weeks (biochemical + confirmatory Sanger)
Clinical Utility	Definitive molecular diagnosis, carrier testing, prenatal planning	Suggestive biochemical abnormality requiring genetic confirmation

Physician Insight & Safety Protocols

"As a Consultant Medical Geneticist, I understand the profound emotional weight that genetic testing for peroxisomal disorders carries for families. While a positive result can guide critical early interventions and accurate prognosis, I always emphasise that clinical correlation with neurological examination, brain imaging, and metabolic findings remains paramount before any medical decision. Your multidisciplinary team will interpret this result within the full tapestry of your clinical history."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Advisory

⚠️ Medication Warning

Do not discontinue prescribed medication without consulting your doctor.

Patient Safety & Exclusion Criteria

Exclusion Criteria

Individuals unable to provide venous blood or FTA card sample after standard venipuncture precautions.
Lack of prior genetic counselling session to document family pedigree and obtain informed consent (mandatory under Federal Decree‑Law No. 4 of 2016 on Medical Liability).
Known bleeding diathesis that cannot be managed safely for phlebotomy.

Emergency Red Flags

Seek immediate medical attention if you or your child experience sudden neurological deterioration, intractable seizures, severe hypotonia, or signs of hepatic dysfunction (jaundice, coagulopathy) while awaiting test results.

Patient FAQ & Clinical Guidance

1. What is the PEX1 gene and its role in peroxisome disorders?

Snippet Answer: The PEX1 gene encodes a peroxisomal biogenesis protein essential for peroxisome formation, and pathogenic variants disrupt the import of enzymes causing Zellweger spectrum disorders like type 1B.

2. Who should consider this PEX1 genetic test?

Snippet Answer: Infants, children or adults presenting with unexplained neurological regression, hypotonia, seizures, sensorineural hearing loss, and retinopathy, especially when accompanied by suggestive biochemical findings.

3. How accurate is the Genetic Test for PEX1 mutations?

Snippet Answer: With >99.9% analytical sensitivity and specificity, this NGS test reliably detects single nucleotide variants and small insertions/deletions across the entire PEX1 coding region.

UAE Regulatory & Data Privacy Adherence

Data Privacy: All genetic data is processed in compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.

Informed Consent: Required per Federal Decree‑Law No. 4 of 2016 on Medical Liability.

Accreditation: Molecular work performed under ISO 9001:2015 certified laboratory (Cert: INT/EGQ/2509DA/3139). LOINC code 48006-3.

Clinical & Logistical Metadata

Test Name	PEX1 Gene Peroxisome Biogenesis Disorder Type 1B Genetic Test
Price (AED)	2,800
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Whole blood (Venous) or FTA card sample
Methodology Used	Next‑Generation Sequencing (NGS)
ICD-10-CM Code	E71.510
LOINC Code	48006-3
DHA Facility License & Address	License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE